Cipla, Dr. Reddy’s, and others to collaborate on Molnupiravir Covid trial
Five Indian pharma companies – Cipla, Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, Sun Pharmaceutical Industries, and Torrent Pharmaceuticals will join forces to undertake a clinical trial ... Read More
Divi’s Laboratories to manufacture API of MSD’s Covid drug Molnupiravir
Divi's Laboratories Limited has been selected by pharma giant MSD (known as Merck in the US and Canada) as an authorized manufacturer for the active ... Read More
Dr. Reddy’s Laboratories launches Ertapenem for Injection in US
Dr. Reddy’s Laboratories has launched Ertapenem for Injection, 1 g/vial, a generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial, which has approval ... Read More
Cipla partners with MSD to manufacture and distribute Molnupiravir drug to treat Covid-19
Cipla has entered into a non-exclusive licensing agreement with MSD (called Merck in the US and Canada) for the manufacturing and distribution of Molnupiravir (EIDD-2801/MK-4482), ... Read More
Merck wraps up $1.8bn acquisition of Pandion Therapeutics
Merck has wrapped up its previously announced $1.85 billion acquisition of Massachusetts-based clinical-stage biotech company Pandion Therapeutics. The pharma giant said that it had successfully ... Read More
Merck to acquire US biotech company Pandion Therapeutics for $1.8bn
Merck has agreed to acquire Pandion Therapeutics, a Massachusetts-based clinical-stage biotech company, for about $1.85 billion in an all-cash deal. Pandion Therapeutics is engaged in ... Read More
Day One Biopharmaceuticals, Merck sign licensing deal for MEK Inhibitors
Day One Biopharmaceuticals has signed a licensing agreement with Merck to develop and commercialize pimasertib and MSC2015103B, two oral, small molecule allosteric inhibitors of MEK ... Read More
Merck seeks FDA and EMA approvals for V114 pneumococcal conjugate vaccine candidate
V114 pneumococcal conjugate vaccine candidate : Merck has submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval ... Read More
Merck to acquire OncoImmune for Covid-19 drug candidate CD24Fc
Merck acquisition of OncoImmune : Pharma giant Merck has signed an all-cash deal worth $425 million to acquire OncoImmune to gain access to the latter’s ... Read More
Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline
Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash ... Read More